Effect of rosiglitazone and 15-deoxy-Δ12, 14-prostaglandin J2 on bleomycin-induced lung injury

European Respiratory Journal

Volumn 25, Issue 2, 2005, Pages 225-234

  Genovese, T ^a   Cuzzocrea, Salvator ^a   Di Paola, R ^a   Mazzon, E ^a   Mastruzzo, C ^b   Catalano, P ^a   Sortino, M ^b   Crimi, N ^b   Caputi, A P ^a   Thiemermann, C ^c   Vancheri, C ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

15 deoxy 12, 14 prostaglandin J2; Bleomycin; Lung injury; Peroxisome proliferator activated receptor ; Rosiglitazone

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 3 NITROTYROSINE; BISPHENOL A BIS(2 HYDROXYPROPYL) ETHER DIMETHACRYLATE; BLEOMYCIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MYELOPEROXIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ROSIGLITAZONE;

AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SYNTHESIS; IMMUNOREACTIVITY; LUNG EDEMA; LUNG INJURY; MALE; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTECTION; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; BIOPSY; BLEOMYCIN; EPOXY COMPOUNDS; IMMUNOENZYME TECHNIQUES; INSTILLATION, DRUG; MALE; MICE; NITRIC OXIDE SYNTHASE; PEROXIDASE; POLY(ADP-RIBOSE) POLYMERASES; PROSTAGLANDIN D2; PULMONARY FIBROSIS; RANDOM ALLOCATION; THIAZOLIDINEDIONES; TYROSINE; WEIGHT LOSS;

EID: 13844294429     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00049704     Document Type: Article

References (40)

1. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517-525.
2. Crouch E. Pathobiology of pulmonary fibrosis. Am J Physiol 1990; 259: L159-L184.
3. Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984; 310: 154-166.
4. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120: 617-624.
5. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001; 21: 185-210.
6. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
7. Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000; 448: 121-138.
8. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000; 40: 491-518.
9. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
10. 2 attenuates the development of acute and chronic inflammation. Mol Pharmacol 2002; 61: 997-1007.
11. 2 synthase suppresses lung injury induced by bleomycin. Am J Respir Cell Mol Biol 2003; 28: 582-591.
12. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354: 141-148.
13. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000; 106: 1305-1307.
14. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995; 270: 12953-12956.
15. Willson TM, Cobb JE, Cowan DJ. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-668.
16. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-3410.
17. Wright HM, Clish CB, Mikami T, et al. A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation. J Biol Chem 2000; 275: 1873-1877.
18. Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eur J Pharmacol. 2004; 483: 79-93.
19. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-470.
20. 2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br J Pharmacol 2003; 138: 678-688.
21. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985; 14: 157-167.
22. Katzenstein AA, Myers JL. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315.
23. Anon. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.
24. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present and future. Chest 1996; 110: 1058-1067.
25. Douglas WW, Ryu JH, Bjoraker JA, et al. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997; 72: 201-209.
26. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double blind, randomized, placebo controlled trial. Am Rev Respir Dis 1991; 144: 291-296.
27. Johnson MA, Kwan S, Snell NJC, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomized controlled trial comparing prednisolone alone with cyclophospamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.
28. Youssef J, Badr M. Peroxisome proliferator-activated receptors. From orphanage to fame in a decade. Saudi Pharm J 2001; 9: 1-13.
29. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459.
30. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.
31. Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med 1996; 2: 87-90.
32. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-3232.
33. Chatham WW, Swaim R, Frohsin H Jr, Heck LW, Miller EJ, Blackburn WD Jr. Degradation of human articular cartilage by neutrophils in synovial fluid. Arthritis Rheum 1993; 36: 51-58.
34. Greene ME, Blumberg B, McBride OW, et al. Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995; 4: 281-299.
35. Bowler RP, Nicks M, Warnick K, Crapo JD. Role of extracellular superoxide dismutase in bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002; 282: L719-L726.
36. Szabó C, Lim LHK, Cuzzocrea S, et al. Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment. J Exp Med 1997; 186: 1041-1049.
37. Szabó C, Viràg L, Cuzzocrea S, et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly (ADP-ribose) synthetase. Proc Natl Acad Sci USA 1998; 9: 3867-3872.
38. Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator-activated receptor γ activators inhibit interleukin-lβ-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 2001; 44: 595-607.
39. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998; 393: 790-793.
40. Karin M. The NF-κB activation pathway: its regulation and role in inflammation and cell survival. Cancer J Sci Am 1998; 4: Suppl. 1, S92-S99.